Pengfei Ren

617 total citations
26 papers, 474 citations indexed

About

Pengfei Ren is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Pengfei Ren has authored 26 papers receiving a total of 474 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Pulmonary and Respiratory Medicine and 9 papers in Oncology. Recurrent topics in Pengfei Ren's work include Lung Cancer Treatments and Mutations (8 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Glycosylation and Glycoproteins Research (4 papers). Pengfei Ren is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Glycosylation and Glycoproteins Research (4 papers). Pengfei Ren collaborates with scholars based in China, United States and Netherlands. Pengfei Ren's co-authors include Jianhang Jiao, Minfei Wu, Yang Wang, Liping Dai, Yongjun Guo, Guanjie Zhao, Jie Ma, Bing Wei, Chao Shi and Jiuzhou Zhao and has published in prestigious journals such as PLoS ONE, Analytical Chemistry and Cancer Research.

In The Last Decade

Pengfei Ren

25 papers receiving 470 citations

Peers

Countries citing papers authored by Pengfei Ren

Since Specialization

Citations

This map shows the geographic impact of Pengfei Ren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pengfei Ren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pengfei Ren more than expected).

Fields of papers citing papers by Pengfei Ren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pengfei Ren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pengfei Ren. The network helps show where Pengfei Ren may publish in the future.

Co-authorship network of co-authors of Pengfei Ren

This figure shows the co-authorship network connecting the top 25 collaborators of Pengfei Ren. A scholar is included among the top collaborators of Pengfei Ren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pengfei Ren. Pengfei Ren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A nomogram based on autoantibodies for noninvasive detection of AFP-negative hepatocellular carcinoma: a multicenter study 2025 ·British Journal of Cancer ·Keyan Wang, (unknown), (unknown), Qing Li, Pengfei Ren, Hua Ye, (unknown), Renle Du, Jianxiang Shi, Peng Wang, (unknown)	0
2	Abstract 1586: KH815, a novel dual-payload TROP2-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model 2025 ·Cancer Research ·(unknown), Pengfei Ren, (unknown), Jiao Tang, Lu Qi, Xinzou Fan, Shi‐Jun Yin, Gang Lei, Ke Xiao	2
3	Abstract 1585: KH815, a novel dual-payload TROP2-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model 2025 ·Cancer Research ·(unknown), Pengfei Ren, (unknown), Jiao Tang, Lu Qi, Xinzou Fan, Shi‐Jun Yin, Gang Lei, Ke Xiao	2
4	4-Coumarate-CoA ligase (4-CL) enhances flavonoid accumulation, lignin synthesis, and fruiting body formation in Ganoderma lucidum 2024 ·Gene ·(unknown), (unknown), (unknown), Xizhe Zang, (unknown), Qingji Wang, (unknown), Wei Wang, Zhuang Li, Pengfei Ren	8
5	Effects of p450 Polymorphisms on the Clinical Outcomes of Gefitinib Treatment in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer 2022 ·Genetic Testing and Molecular Biomarkers ·(unknown), Jiuzhou Zhao, Bo Wang, Xiang Li, (unknown), Pengfei Ren, Rui Sun, Liya Zhang, Yongjun Guo	1
6	Industrial Mushroom Residue as Cow Bedding: Analysis of Microbial Diversity and Applications 2021 ·Current Microbiology ·Jie Lian, Ling Qu, Pengfei Ren, (unknown), (unknown), (unknown), Hui Zhang, (unknown), Xia Gao, (unknown)	5
7	MCC950, a Selective Inhibitor of NLRP3 Inflammasome, Reduces the Inflammatory Response and Improves Neurological Outcomes in Mice Model of Spinal Cord Injury 2020 ·Frontiers in Molecular Biosciences ·Jianhang Jiao, Guanjie Zhao, Yang Wang, Pengfei Ren, Minfei Wu	78
8	<p>Effectiveness and Feasibility of Complementary Lung-RADS Version 1.1 in Risk Stratification for pGGN in LDCT Lung Cancer Screening in a Chinese Population</p> 2020 ·Cancer Management and Research ·Qingcheng Meng, Pengfei Ren, (unknown), (unknown), (unknown), Lanwei Guo, (unknown)	5
9	Identification of novel autoantibodies based on the protein chip encoded by cancer-driving genes in detection of esophageal squamous cell carcinoma 2020 ·OncoImmunology ·Guiying Sun, Hua Ye, Xiao Wang, Lin Cheng, Pengfei Ren, Jianxiang Shi, Liping Dai, Peng Wang, Jianying Zhang	12
10	Necrosulfonamide Ameliorates Neurological Impairment in Spinal Cord Injury by Improving Antioxidative Capacity 2020 ·Frontiers in Pharmacology ·Jianhang Jiao, Yang Wang, Pengfei Ren, (unknown), Minfei Wu	41
11	The clinical significance of serum adipocytokines level in patients with lung cancer 2019 ·Journal of Thoracic Disease ·Fanfan Li, Yanan Cao, Jingjing Li, Cong Gao, Xiang Da Dong, Pengfei Ren, (unknown), Chanjuan Chen	11
12	[Early diagnosis of subtype in early clinical stage lung adenocarcinoma by using an autoantibody panel and computed tomography]. 2019 ·PubMed ·Qingcheng Meng, Pan Gao, Pengfei Ren, Yongping Song, (unknown)	3
13	A circular RNA from APC inhibits the proliferation of diffuse large B-cell lymphoma by inactivating Wnt/β-catenin signaling via interacting with TET1 and miR-888 2019 ·Aging ·Yanping Hu, (unknown), Chao Shi, Pengfei Ren, Bing Wei, Yongjun Guo, Jie Ma	48
14	Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma 2018 ·PLoS ONE ·Yingying Tian, Jiuzhou Zhao, Pengfei Ren, Bo Wang, (unknown), Chao Shi, Bing Wei, Jie Ma, Yongjun Guo	19
15	A comparative study of EGFR oncogenic mutations in matching tissue and plasma samples from patients with advanced non-small cell lung carcinoma 2016 ·Clinica Chimica Acta ·(unknown), Pengfei Ren, Bing Wei, Jie Ma, Ling Mai, David S. Cram, (unknown), Yongjun Guo	26
16	Autoantibody response to a novel tumor-associated antigen p90/CIP2A in breast cancer immunodiagnosis 2014 ·Tumor Biology ·Xinxin Liu, Yurong Chai, Jitian Li, Pengfei Ren, Mei Liu, Liping Dai, Wei Qian, Wenjie Li, Jian-Ying Zhang	17
17	Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma 2014 ·Clinical Immunology ·Liping Dai, Pengfei Ren, Mei Liu, Haruhiko Imai, Eng M. Tan, (unknown)	47
18	HapMap-based study of CIP2A gene polymorphisms and HCC susceptibility 2012 ·Oncology Letters ·Yuchun Li, Kaijuan Wang, Liping Dai, Peng Wang, Chunhua Song, Jianxiang Shi, Pengfei Ren, Hua Ye, Jianying Zhang	6
19	Autoantibodies against glucose-regulated protein 78 as serological diagnostic biomarkers in hepatocellular carcinoma 2012 ·International Journal of Oncology ·Qing Shao, Pengfei Ren, Yang Li, Bo Peng, Liping Dai, Ningjing Lei, (unknown), (unknown), (unknown), Jianying Zhang	36
20	Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer 2012 ·Oncology Letters ·Hua Ye, Changqing Sun, Pengfei Ren, Liping Dai, Bo Peng, Kaijuan Wang, Wei Qian, Jianying Zhang	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact